Neumora Therapeutics, Inc. Common Stock
NMRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $294,545 | $118,568 | $161,451 | $1,706,430 |
| - Cash | $129,071 | $124,523 | $126,860 | $142,148 |
| + Debt | $523 | $510 | $938 | $1,853 |
| Enterprise Value | $165,997 | -$5,445 | $35,529 | $1,566,135 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$5,000 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$55,985 | -$54,021 | -$70,779 | -$62,765 |
| % Margin | – | – | – | – |
| Net Income | -$56,755 | -$52,731 | -$67,992 | -$58,819 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.35 | -0.33 | -0.42 | -0.37 |
| % Growth | -6.1% | 21.4% | -13.5% | – |
| Operating Cash Flow | -$46,633 | -$52,404 | -$59,448 | -$50,340 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$46,649 | -$52,404 | -$59,448 | -$50,340 |